The rapid evolution and expansion of applications in targeted cell therapies and immunobiologics has seen significant interest in the use of biological therapies for treating disease, resulting in an evolving and complex patent space.
Challenges in product efficacy, administration, side effects and costs are driving ongoing research, with IP considerations spanning the preparation of cells, formulations and methods of administration.
HGFs team of 23 life sciences attorneys, who possess specific immunobiology academic accomplishments and in-house backgrounds, apply a cross-technology approach to building portfolios and data-driven strategies that layer protection and maximise exclusivity periods.
The team’s extensive insight into regulatory and approval pathways in this area adds a strong commercial focus to the development of economically viable strategies. Furthermore, the multidisciplinary specialists have significant experience in conducting due diligence across every aspect of immunobiology, from genes through to formulation and application processes.
Working with universities, large pharmaceutical firms and generic companies, HGF creates and protects patents for commercially important products, with significant experience of opposition and appeals before the European Patent Office.
HGF’s Partner Dr Markus Zoller is attending and speaking at the German Biotechnology days on 20th September 2021. German Biotechnology days is the go to event in the industry and …Event details
The IAM Patent 1000 – the world’s leading patent professionals 2021 guide has now been published. HGF has 18 European attorneys listed. IAM Patent 1000 is a unique guide that …Read article
Pharmaceutical and biotechnology patent applications also make top 10 most patented. Recent statistics published by the EPO show that a total of 14,295 European patent applications were filed in 2020 …Read article
How to streamline the trade mark selection process by conducting effective, in-house ‘dirty searches’. Selecting the right trade mark for your new healthcare product is a critically important task. Consumers …Read article
The 2021 EPO Guidelines provide much needed guidance on how to protect antibodies in Europe. Biological drugs including therapeutic antibodies have become increasingly important to the pharmaceutical industry. The European …Read article
Opportunities for additional pharmaceutical product patent protection in Europe, based on the use of a drug to treat a patient exhibiting a biomarker indicative of drug response. Recent years have …Read article
Exploring the growth of patents for connected medical devices, and how best to protect them. The Internet of Things (IoT) is expected to change our lives by creating a connected …Read article
To waive, or not to waive, that is the question. The earliest identified date of a patient presenting with symptoms of a “novel coronavirus” in Wuhan, China is reported to …Read article